Skip to content
Tech News
← Back to articles

America’s Health Care System Is So Screwed That Patients Are Flying to China for Cancer Treatment

read original more articles
Why This Matters

CAR-T cancer therapy was pioneered in the US, but American pricing ($550K–$850K) and supply shortages are pushing patients to Shanghai, where the same treatment runs $150K–$230K and is delivered faster. It's a stark example of how China has industrialized a US-invented biotech and turned a cutting-edge therapy into an export service. For US healthcare and biotech, it signals lost competitive ground and a growing medical tourism pipeline for even the most advanced treatments.

Key Takeaways

Sign up to see the future, today Can’t-miss innovations from the bleeding edge of science and tech Email address Sign Up Thank you!

The myriad horrors of the US healthcare system have spawned generations of medical tourism from the wealthiest country on Earth to the periphery: Cuba, Mexico, Costa Rica, Canada, Turkey, and Thailand, to name just a few.

Now, Shanghai is quickly rising as one of the top destinations for cancer patients, as China’s biotech sector has spun an experimental treatment developed in the US into a standalone industry.

New reporting by the Wall Street Journal took a look at this fast-growth industry, centered around chimeric antigen receptor T-cell therapy, or CAR-T for short.

CAR-T is essentially a personalized form of immunotherapy, in which a patient’s own white blood cells are engineered to identify and attack specific proteins found in cancer cells. Though the process was first developed by US biotech giants, their inability — or unwillingness — to lower the cost and increase supply of the treatment has led to shortages throughout the country.

That’s where China comes in. As director of the CAR-T program at the University of Texas MD Anderson Cancer Center in Houston Sairah Ahmed told the WSJ, this therapy can cost around $150,000 to $230,000 in China — still a life-altering bill, but a sizeable discount compared to an insurmountable $550,000 to $850,000 in the US.

This, Ahmed says, is why she advises some patients to seek out treatment in the People’s Republic.

“China has basically done to CAR-T cell therapy the same thing that it’s done to other industries, which is, they’ve industrialized it,” Ahmed explained.

China’s CAR-T services aren’t just cheaper, either. They’re also faster, and come with a host of complimentary after-care treatments, the WSJ notes. As MD Anderson Cancer Center’s explainer on CAR-T therapy advises, the process of extracting and bio-engineering a patient’s cells to fight cancer can take over three weeks in the US. Compare that to China, where the WSJ reports labs near Shanghai can “crank out” the therapy in just a matter of days.

An important caveat here is that CAR-T cell therapy isn’t a catch-all for every type of cancer, and it’s typically only administered after other treatments have failed. It’s not exactly a walk in the park, either, requiring months of recovery and check-ups from a range of physical, neurological, and psychological health specialists. Still, if you had to go through with it, your first step should clearly be pricing out some flights to China.

... continue reading